Case Study 16.1 — Dr. Hernandez and the R01

A composite, illustrative case. Dr. Elena Hernandez and the specifics of her review are constructed to teach; the NIH structures, mechanisms, and processes are real. Verify all current details at grants.nih.gov.

The investigator and the question

Dr. Elena Hernandez is an early-stage investigator at a mid-sized research university. Her work asks whether a text-message medication-adherence intervention can improve glycemic control in adults with type 2 diabetes — a behaviorally grounded, clinically meaningful question with a clear public-health stake. She has run a small pilot: encouraging effect sizes, a workable recruitment pathway through one clinic partner, and a defined protocol. She is, in NIH terms, exactly the kind of investigator the system is built to launch — a strong question, real but modest preliminary data, and ESI (Early-Stage Investigator) status.

The chapter's machinery now becomes her lived reality. Watch how each decision maps to a section of Chapter 16.

Decision 1 — The mechanism (Section 16.2)

Hernandez faces the classic fork: an R21 (exploratory, no preliminary data required, smaller and shorter — good for de-risking a thin idea) or the R01 (the workhorse, funds a substantial multi-year project, rewards preliminary data). Her ambition says R01; the threshold concept says match the mechanism to your stage and evidence, not your ambition. So she tests it honestly: is her evidence R01-grade?

It is, just. Her pilot is solid, her trial design is fully developed, and — decisively — she has ESI status, which means many institutes will apply a more forgiving payline to her R01. She talks it through with her program officer, who agrees the R01 is reasonable given the developed design and the ESI advantage. Had her data been thinner, the R21 would have been the wiser first move, generating the evidence to support a later R01. The lesson lands: the mechanism choice is strategic and stage-dependent, and Hernandez passes the threshold test rather than failing it.

Decision 2 — Influencing the assignment (Section 16.1)

Hernandez knows review is split from funding. She writes a cover letter (Chapter 7) requesting assignment to the diabetes-focused institute (whose mission her work advances) and to a study section with behavioral-intervention and diabetes expertise (which will review her fairly). CSR honors the request. This is not a small thing: had she landed in a study section without behavioral-trial expertise, or an institute that didn't prioritize diabetes self-management, no amount of polish could have fully compensated.

Decision 3 — Writing for two rooms (Sections 16.3–16.4)

She writes a sharp Specific Aims page (Chapter 6) — because she knows her primary reviewer will essentially re-present her aims and approach to a panel that hasn't read the full application (Chapter 2). She makes Significance unmistakable (Chapter 8), and she invests her most careful work in Approach (Chapter 9), knowing it's often the most heavily weighted criterion and that the holistic score lets one weak dimension dominate. She handles the NIH-specific components (Section 16.5) with real care: a genuine Rigor and Reproducibility account, an inclusion plan reflecting the diabetes-affected population, a Data Management and Sharing plan, NIH-format biosketches.

What happened at review

CSR assigns the application as requested. Three reviewers read it in full and score it preliminarily; it scores well enough to be discussed rather than triaged. At the meeting the primary reviewer presents it — re-delivering Hernandez's aims and approach from memory — praising the significance and the solid design but raising one concern: recruitment feasibility, given that her pilot ran through a single clinic. The panel discusses briefly, then everyone scores it.

Her averaged, ×10 overall impact score lands at 28, around the 18th percentile. The institute's payline this cycle is the 15th percentile.

She is just below the line. Not funded — but with a competitive score and a summary statement whose central critique (recruitment) is specific and fixable. In the chapter's terms, she is in a strong position: this is the classic A1 setup, and most funded R01s looked exactly like this on the first try.

Decision 4 — The program-officer call (Section 16.6)

Hernandez calls her program officer. The PO confirms the score is competitive, encourages an A1, and gives a candid read on the critiques: which to address most seriously (recruitment), and which a reviewer may have somewhat misunderstood. This conversation — the kind of high-value contact Chapter 2 urged — shapes her whole resubmission strategy.

Decision 5 — The A1 (Section 16.6, Chapter 22)

Hernandez prepares her A1 resubmission:

• She strengthens the weak point. She adds a second clinic partner with a commitment letter (Chapter 13) and includes pilot recruitment data demonstrating feasibility — converting the reviewers' doubt into evidence.
• She writes the required introduction-to-resubmission (Chapter 22), responding point by point to the summary statement: agreeing and fixing where the critiques are right (recruitment), and briefly, respectfully clarifying where a reviewer misread a detail — never defensive, always responsive.
• She demonstrates that she listened. Because the same study section often re-reviews the A1, her job is partly to show the panel their concerns were taken seriously.

Her A1, with the recruitment concern resolved and responsiveness demonstrated, scores above the payline and is funded.

What this case teaches

1. The machinery is decisive, not decorative. Hernandez's science was strong throughout — but it was the mechanism choice, the assignment, the aims page, the holistic Approach, the PO relationship, and the A1 that turned strong science into funding.
2. A near-miss is a strong position, not a failure. A 28 at the 18th percentile, just below a 15th-percentile payline, is the normal path to a funded R01. Reading "rejected" as "not yet" is the single most important reframe in NIH funding.
3. The summary statement is the asset. Her funded A1 existed because the A0 critique was specific and she answered it. Without the rejection's feedback, she'd have had nothing to improve.
4. The threshold concept held. She matched the mechanism (R01) to her stage (ESI) and evidence (developed pilot and design) — not merely to her ambition — and that honest match put her in the game.

🔄 Retrieve: Without rereading, state (a) why Hernandez's just-below-payline A0 was a good position, and (b) the two things her A1 had to accomplish. (Answers in the narrative above.)